Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aura Biosciences (AURA) Shares Outstanding (2020 - 2026)

Aura Biosciences filings provide 7 years of Shares Outstanding readings, the most recent being $64.2 million for Q1 2026.

  • Quarterly Shares Outstanding rose 27.73% to $64.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $64.2 million through Mar 2026, up 27.73% year-over-year, with the annual reading at $63.6 million for FY2025, 27.18% up from the prior year.
  • Shares Outstanding hit $64.2 million in Q1 2026 for Aura Biosciences, up from $63.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $64.2 million in Q1 2026 and bottomed at $29.2 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $46.5 million, with a median of $49.5 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding skyrocketed 36369.14% in 2022 before it rose 1.31% in 2024.
  • Aura Biosciences' Shares Outstanding stood at $37.8 million in 2022, then surged by 30.65% to $49.4 million in 2023, then rose by 1.31% to $50.0 million in 2024, then increased by 27.18% to $63.6 million in 2025, then increased by 0.88% to $64.2 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Shares Outstanding are $64.2 million (Q1 2026), $63.6 million (Q4 2025), and $63.0 million (Q3 2025).